Ilshat R. Gaisin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilshat R. Gaisin has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Evgeny K. Kochurov
Izhevsk State Medical University
3 shared publications - A. S. Iskhakova
Clinical Diagnostic Centre of the Udmurt Republic
2 shared publications - Azat S. Galeev
City Polyclinic No. 1
2 shared publications S. A. Pomosov
Clinical Diagnostic Centre, Healthcare Ministry of Udmurt Republic
2 shared publicationsA. S. Gazimzyanova
Бюджетное учреждение здравоохранения Удмуртской Республики «Республиканский клинико-диагностический центр» Министерства здравоохранения Удмуртской Республики
1 shared publication- Albert S. Galyavich
Kazan State Medical University
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 153-172
Pregnancy and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Introduction . Metabolic dysfunction‑associated steatotic liver disease (MASLD) demonstrates a significant prevalence among women of reproductive age (approximately 10 %), yet the pathophysiological mechanisms of its impact on gestation remain insufficiently understood, and management algorithms for patients before, during, and after pregnancy are lacking. Purpose of the work is to review the scientific literature and summarise current data on the epidemiology, pathophysiology, and maternal/perinatal risks of MASLD in pregnancy, and to present diagnostic and therapeutic strategies from pregravid through postpartum care. Materials and methods . A search of articles was conducted in the PubMed database using the following keywords: metabolic dysfunction-associated steatotic liver disease, MASLD, pregnancy, gestational diabetes mellitus, obesity, pregnancy outcomes. Results and discussion . MASLD is highly prevalent among women of reproductive age and during pregnancy and associated with higher risk of developing gestational diabetes, pre-eclampsia, and preterm birth. Currently, there are no guidelines for routine screening for MASLD during pregnancy; however, women with metabolic disorders are recommended to undergo imaging investigations and laboratory panels to assess liver function. Liver fibrosis assessment should be performed before pregnancy to identify cases of cirrhosis. For women with MASLD, acetylsalicylic acid is recommended to reduce pre-eclampsia risk. In the absence of cirrhosis signs, additional monitoring of liver function is not required. Breastfeeding has been associated with beneficial effects on maternal and child metabolic health. Conclusion . MASLD prevalence in pregnancy is rising, increasing risks of adverse maternal and perinatal outcomes. Further studies on long‑term risks and safety of MASLD therapy during gestation and lactation are needed.
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 153-172
Open AccessPregnancy and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Introduction . Metabolic dysfunction‑associated steatotic liver disease (MASLD) demonstrates a significant prevalence among women of reproductive age (approximately 10 %), yet the pathophysiological mechanisms of its impact on gestation remain insufficiently understood, and management algorithms for patients before, during, and after pregnancy are lacking. Purpose of the work is to review the scientific literature and summarise current data on the epidemiology, pathophysiology, and maternal/perinatal risks of MASLD in pregnancy, and to present diagnostic and therapeutic strategies from pregravid through postpartum care. Materials and methods . A search of articles was conducted in the PubMed database using the following keywords: metabolic dysfunction-associated steatotic liver disease, MASLD, pregnancy, gestational diabetes mellitus, obesity, pregnancy outcomes. Results and discussion . MASLD is highly prevalent among women of reproductive age and during pregnancy and associated with higher risk of developing gestational diabetes, pre-eclampsia, and preterm birth. Currently, there are no guidelines for routine screening for MASLD during pregnancy; however, women with metabolic disorders are recommended to undergo imaging investigations and laboratory panels to assess liver function. Liver fibrosis assessment should be performed before pregnancy to identify cases of cirrhosis. For women with MASLD, acetylsalicylic acid is recommended to reduce pre-eclampsia risk. In the absence of cirrhosis signs, additional monitoring of liver function is not required. Breastfeeding has been associated with beneficial effects on maternal and child metabolic health. Conclusion . MASLD prevalence in pregnancy is rising, increasing risks of adverse maternal and perinatal outcomes. Further studies on long‑term risks and safety of MASLD therapy during gestation and lactation are needed.
- Open Access
- 20 September 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (4) , 5-19
Metabolic dysfunction-associated steatotic liver disease and cardiovascular pathology
The data on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its phenotypes, the evolution of steatotic liver disease terminology and its association with cardiovascular diseases were summarized. A systematic search for relevant publications in the PubMed database was performed. MASLD has become one of the most prevalent and underappreciated cardiovascular threats. It is closely associated with the development and progression of atherosclerotic cardiovascular diseases, arrhythmias, conduction disorders, hypertension and heart failure. Moreover, MASLD is a crucial part of the cardiohepatorenal continuum. Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.
- 20 September 2026
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 43 (4) , 5-19
Open AccessMetabolic dysfunction-associated steatotic liver disease and cardiovascular pathology
The data on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its phenotypes, the evolution of steatotic liver disease terminology and its association with cardiovascular diseases were summarized. A systematic search for relevant publications in the PubMed database was performed. MASLD has become one of the most prevalent and underappreciated cardiovascular threats. It is closely associated with the development and progression of atherosclerotic cardiovascular diseases, arrhythmias, conduction disorders, hypertension and heart failure. Moreover, MASLD is a crucial part of the cardiohepatorenal continuum. Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.
- 31 March 2026
- Published by Izhevsk State Medical Academy in Health, demography, ecology of finno-ugric peoples
- No. 1,p. 72-75
Жизнь посвятил сердцам. К 75-летнему юбилею профессора Максимова Николая Ивановича
В январе 2026 года исполнилось 75 лет ведущему кардиологу, заслуженному деятелю науки Удмуртской Республики, заслуженному врачу Российской Федерации, доктору медицинских наук, профессору Максимову Николаю Ивановичу, и 50 лет с начала его научно-практической деятельности. In January 2026, Nikolai Ivanovich Maksimov, a leading cardiologist, Honored Scientist of the Udmurt Republic, Honored Doctor of the Russian Federation, Doctor of Medical Sciences, and Professor, celebrated his 75th birthday, as well as the 50th anniversary of his scientific and practical career.
- 31 March 2026
- Published by Izhevsk State Medical Academy in Health, demography, ecology of finno-ugric peoples
- No. 1,p. 72-75
Жизнь посвятил сердцам. К 75-летнему юбилею профессора Максимова Николая Ивановича
В январе 2026 года исполнилось 75 лет ведущему кардиологу, заслуженному деятелю науки Удмуртской Республики, заслуженному врачу Российской Федерации, доктору медицинских наук, профессору Максимову Николаю Ивановичу, и 50 лет с начала его научно-практической деятельности. In January 2026, Nikolai Ivanovich Maksimov, a leading cardiologist, Honored Scientist of the Udmurt Republic, Honored Doctor of the Russian Federation, Doctor of Medical Sciences, and Professor, celebrated his 75th birthday, as well as the 50th anniversary of his scientific and practical career.
- 26 December 2025
- Published by Izhevsk State Medical Academy in Health, demography, ecology of finno-ugric peoples
- No. 4,p. 39-48
НОВЫЙ, КАРДИОГЕПАТОРЕНАЛЬНЫЙ, КОНТИНУУМ: ЧАСТЬ II
Цель исследования: проанализировать эффективность и безопасность традиционных и новых немедикаментозных и медикаментозных терапевтических подходов на различных этапах кардиогепаторенального континуума. Материалы и методы исследования. В базе данных PubMed проведен поиск актуальных статей с использованием ключевых слов: atherosclerotic cardiovascular diseases, ASCVD, heart failure, HF, chronic kidney disease, CKD, non-alcoholic fatty liver disease, NAFLD, metabolic dysfunction-associated fatty liver disease, MAFLD, metabolic dysfunction-associated steatotic liver disease, MASLD, prevention, treatment. Предпочтение отдавалось рандомизированным клиническим исследованиям, систематическим анализам и мета-анализам. Результаты исследования. Данные о значительном благоприятном влиянии качества питания и модификации образа жизни как на кардиоренальное здоровье, так и на метаболически-ассоциированную стеатотическую болезнь печени (МАСБП), указывают на необходимость создания благоприятной среды, обеспечивающей приверженность здоровому образу жизни. Аспирин благоприятно влияет на печеночные исходы пациентов с МАСБП. Статины эффективны и безопасны на протяжении практически всего печеночного континуума. Прием статинов ассоциирован с более благоприятными сердечно-сосудистыми исходами у пациентов с МАСБП, а также, вероятно, способствует замедлению прогрессирования хронической болезни почек (ХБП). Эффективность и безопасность ингибиторов натрий-глюкозного ко-транспортера 2 типа, агонистов инкретиновых рецепторов и нестероидных антагонистов минералокортикоидных рецепторов (АМР) при всех фенотипах сердечной недостаточности (СН) независимо от степени дисфункции почек и наличия ожирения или диабета делают их ключевыми препаратами в ведении пациентов на разных этапах кардиогепаторенального континуума. Кроме того, эти препараты оказывают благоприятное влияние на печеночные, почечные и сердечно-сосудистые исходы при МАСБП. Блокаторы ренин-ангиотензиновой системы, стероидные АМР, блокаторы кальциевых каналов, бета-блокаторы и метформин не оказывают влияния на прогрессирование МАСБП. Необходимы дальнейшие исследования для определения их безопасности и эффективности при МАСБП. Перспективными болезнь-модифицирующими препаратами при МАСБП являются ресметиром (первое и пока единственное одобренное FDA антифибротическое средство), другие агонисты β-рецепторов тироидных гормонов и модуляторы гепатокинов, в частности аналог фактора роста фибробластов 21 эфруксифермин. Заключение. Кардиогепаторенальный континуум — новый подход к пониманию развития и прогрессирования метаболических расстройств, атеросклеротических сердечно-сосудистых заболеваний (АССЗ), СН, ХБП и МАСБП, являющихся одной из основных проблем современного здравоохранения. Прерывая этот континуум, можно предотвратить или замедлить развитие и прогрессирование заболеваний сердца, почек и печени. Ведение пациентов с метаболическими расстройствами, МАСБП, АССЗ и ХБП требует комплексного подхода с принятием во внимание сложной взаимосвязи заболеваний, индивидуальных особенностей и коморбидностей пациента. Aim: to analyse the efficacy and safety of traditional and new non-drug and drug therapeutic approaches at different stages of the cardiohepatorenal continuum. Materials and methods. A comprehensive literature review was conducted to identify relevant studies using electronic database PubMed. Key terms included «atherosclerotic cardiovascular diseases», «ASCVD», «heart failure», «HF», «chronic kidney disease», «CKD», «non-alcoholic fatty liver disease», «NAFLD», «metabolic...
- 26 December 2025
- Published by Izhevsk State Medical Academy in Health, demography, ecology of finno-ugric peoples
- No. 4,p. 39-48
НОВЫЙ, КАРДИОГЕПАТОРЕНАЛЬНЫЙ, КОНТИНУУМ: ЧАСТЬ II
Цель исследования: проанализировать эффективность и безопасность традиционных и новых немедикаментозных и медикаментозных терапевтических подходов на различных этапах кардиогепаторенального континуума. Материалы и методы исследования. В базе данных PubMed проведен поиск актуальных статей с использованием ключевых слов: atherosclerotic cardiovascular diseases, ASCVD, heart failure, HF, chronic kidney disease, CKD, non-alcoholic fatty liver disease, NAFLD, metabolic dysfunction-associated fatty liver disease, MAFLD, metabolic dysfunction-associated steatotic liver disease, MASLD, prevention, treatment. Предпочтение отдавалось рандомизированным клиническим исследованиям, систематическим анализам и мета-анализам. Результаты исследования. Данные о значительном благоприятном влиянии качества питания и модификации образа жизни как на кардиоренальное здоровье, так и на метаболически-ассоциированную стеатотическую болезнь печени (МАСБП), указывают на необходимость создания благоприятной среды, обеспечивающей приверженность здоровому образу жизни. Аспирин благоприятно влияет на печеночные исходы пациентов с МАСБП. Статины эффективны и безопасны на протяжении практически всего печеночного континуума. Прием статинов ассоциирован с более благоприятными сердечно-сосудистыми исходами у пациентов с МАСБП, а также, вероятно, способствует замедлению прогрессирования хронической болезни почек (ХБП). Эффективность и безопасность ингибиторов натрий-глюкозного ко-транспортера 2 типа, агонистов инкретиновых рецепторов и нестероидных антагонистов минералокортикоидных рецепторов (АМР) при всех фенотипах сердечной недостаточности (СН) независимо от степени дисфункции почек и наличия ожирения или диабета делают их ключевыми препаратами в ведении пациентов на разных этапах кардиогепаторенального континуума. Кроме того, эти препараты оказывают благоприятное влияние на печеночные, почечные и сердечно-сосудистые исходы при МАСБП. Блокаторы ренин-ангиотензиновой системы, стероидные АМР, блокаторы кальциевых каналов, бета-блокаторы и метформин не оказывают влияния на прогрессирование МАСБП. Необходимы дальнейшие исследования для определения их безопасности и эффективности при МАСБП. Перспективными болезнь-модифицирующими препаратами при МАСБП являются ресметиром (первое и пока единственное одобренное FDA антифибротическое средство), другие агонисты β-рецепторов тироидных гормонов и модуляторы гепатокинов, в частности аналог фактора роста фибробластов 21 эфруксифермин. Заключение. Кардиогепаторенальный континуум — новый подход к пониманию развития и прогрессирования метаболических расстройств, атеросклеротических сердечно-сосудистых заболеваний (АССЗ), СН, ХБП и МАСБП, являющихся одной из основных проблем современного здравоохранения. Прерывая этот континуум, можно предотвратить или замедлить развитие и прогрессирование заболеваний сердца, почек и печени. Ведение пациентов с метаболическими расстройствами, МАСБП, АССЗ и ХБП требует комплексного подхода с принятием во внимание сложной взаимосвязи заболеваний, индивидуальных особенностей и коморбидностей пациента. Aim: to analyse the efficacy and safety of traditional and new non-drug and drug therapeutic approaches at different stages of the cardiohepatorenal continuum. Materials and methods. A comprehensive literature review was conducted to identify relevant studies using electronic database PubMed. Key terms included «atherosclerotic cardiovascular diseases», «ASCVD», «heart failure», «HF», «chronic kidney disease», «CKD», «non-alcoholic fatty liver disease», «NAFLD», «metabolic...
- Open Access
- 22 September 2025
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 1 (3) , 269-285
Kidney Involvement in Spondyloarthritis: A Literature Review
Introduction. Currently, the identification and prevention of renal dysfunction in patients with spondyloarthritis receive insufficient attention, although kidney involvement can significantly determine their prognosis. The aim of this review is to analyze the types, prevalence, and risk factors for the development and progression of renal impairment in spondyloarthritis. Materials and methods. A search for publications was conducted in the PubMed database using keywords for the period 2000–2024. Preference was given to original research, systematic reviews, and meta-analyses. Particular attention was paid to studies including kidney biopsy data, as well as works devoted to long-term patient follow-up. In addition, reference lists of review articles were examined to identify relevant publications. Ultimately, 66 studies were included in the review. Results. Kidney involvement is a frequent complication of spondyloarthritis. The most common manifestations are AA amyloidosis, immunoglobulin A nephropathy, and chronic interstitial nephritis. Furthermore, patients are characterized by a significant prevalence and a greater risk of developing chronic kidney disease. High disease activity and duration, the presence of extra-articular manifestations, patient sex and age, time of diagnosis, the presence of human leukocyte antigen B27, and the levels of C-reactive protein, uric acid, immunoglobulins A and G, and albumin may indicate a high risk of kidney involvement. The use of non-steroidal anti-inflammatory drugs, certain synthetic and biological disease-modifying antirheumatic drugs may be associated with the development of kidney diseases, particularly in the presence of risk factors such as pre-existing renal dysfunction and hypertension. Metabolic disorders have a significant impact on the development and progression of renal dysfunction. Kidney dysfunction, in turn, affects adipose tissue function and the progression of metabolic disorders. Discussion and conclusion. Routine examination of patients with spondyloarthritis is necessary to detect kidney involvement, as well as to identify and correct factors contributing to the development and progression of renal dysfunction in this patient group.
- 22 September 2025
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 1 (3) , 269-285
Open AccessKidney Involvement in Spondyloarthritis: A Literature Review
Introduction. Currently, the identification and prevention of renal dysfunction in patients with spondyloarthritis receive insufficient attention, although kidney involvement can significantly determine their prognosis. The aim of this review is to analyze the types, prevalence, and risk factors for the development and progression of renal impairment in spondyloarthritis. Materials and methods. A search for publications was conducted in the PubMed database using keywords for the period 2000–2024. Preference was given to original research, systematic reviews, and meta-analyses. Particular attention was paid to studies including kidney biopsy data, as well as works devoted to long-term patient follow-up. In addition, reference lists of review articles were examined to identify relevant publications. Ultimately, 66 studies were included in the review. Results. Kidney involvement is a frequent complication of spondyloarthritis. The most common manifestations are AA amyloidosis, immunoglobulin A nephropathy, and chronic interstitial nephritis. Furthermore, patients are characterized by a significant prevalence and a greater risk of developing chronic kidney disease. High disease activity and duration, the presence of extra-articular manifestations, patient sex and age, time of diagnosis, the presence of human leukocyte antigen B27, and the levels of C-reactive protein, uric acid, immunoglobulins A and G, and albumin may indicate a high risk of kidney involvement. The use of non-steroidal anti-inflammatory drugs, certain synthetic and biological disease-modifying antirheumatic drugs may be associated with the development of kidney diseases, particularly in the presence of risk factors such as pre-existing renal dysfunction and hypertension. Metabolic disorders have a significant impact on the development and progression of renal dysfunction. Kidney dysfunction, in turn, affects adipose tissue function and the progression of metabolic disorders. Discussion and conclusion. Routine examination of patients with spondyloarthritis is necessary to detect kidney involvement, as well as to identify and correct factors contributing to the development and progression of renal dysfunction in this patient group.
- Open Access
- 11 March 2022
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 28 (2) , 126-146
Management of arterial hypertension in women after delivery (a literature review)
Ведение артериальной гипертензии у женщин после родов (обзор литературы)
- 11 March 2022
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 28 (2) , 126-146
Open AccessManagement of arterial hypertension in women after delivery (a literature review)
Ведение артериальной гипертензии у женщин после родов (обзор литературы)
- 20 February 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (1) , 53-61
Efficacy of intermittent inhaled iloprost in inoperable chronic thromboembolic pulmonary hypertension
PH (pulmonary hypertension) targeted therapy may play an essential role in chronic thromboembolic pulmonary hypertension (CTEPH) patients considered inoperable. Given the limited number of PH-targeted drugs approved for CTEPH, reliable long-term data are necessary on the effects of PH-targeted drugs in patients with inoperable CTEPH. We aimed to evaluate the efficacy and safety of intermittent inhaled iloprost in inoperable CTEPH. Methods. The open randomized controlled trial included 22 inoperable CTEPH patients (aged (Me (25%; 75%)) 48,3 (38,4; 59,5) years; 63.6% females; 9.1% with WHO functional class (FC) IV, 72.7% with WHO-FC III, 18.2% with WHO-FC II; 6-minute walking test (6-MWT) distance of 348 (145; 443) m; mean pulmonary artery pressure (mPAP) of 41.8 (29.3; 52.8) mmHg; tricuspid annular plane systolic excursion (TAPSE) of 16.3 (14.5; 18.2) mm; plasma NT-proBNP of 853.8 (562.2; 1124.2) pg/mL). The patients were enrolled 3 – 6 months after acute pulmonary embolism and were randomized 1:1 to receive either standard therapy with vitamin K antagonists and, if indicated, oxygen and diuretics or inhaled iloprost 5.0 µg / inhalation 4 times a day for 2 weeks every 3 months for 2 years in addition to the standard of care. Efficacy endpoints included changes from baseline in 6-MWT, WHO-FC, echo-parameters, inflammatory markers, time to clinical worsening, and all-cause mortality. Results. At baseline (prior to therapy), there were no significant differences between iloprost and control groups. Levels of C-reactive protein and the interleukin (IL)-1b, IL-6, IL-8, γ-IF, and TNF-α cytokines were increased. At month 24, a mean 6-MWT distance increased by 215 m (p < 0.001) in the patients receiving inhaled iloprost and by 137 m in the control patients (p < 0.01). The control-adjusted difference was +78 m (p = 0.03). WHO-FC improved by two classes in 63.6% in iloprost group vs 0% in the control group (p = 0.028), by one class in 36.4% vs 30% (p = 0.091), and remained the same in 0% vs 70 % (p = 0.018), respectively. Inhaled iloprost delayed the time to clinical worsening (p = 0.0064). Improvements were noted in control-adjusted changes in ePASP (–18.6 mmHg; p = 0.0065), TAPSE (+2.4 mm; p = 0.028), and plasma NT-proBNP (–256.9 pg/mL; p < 0.01). The levels of inflammation decreased significantly in the iloprost group, while remained unchanged in the control group. Combination therapy with inhaled iloprost was tolerated well. One patient died in the control group (p = 0.093). Conclusion. Long-term intermittent inhaled iloprost for patients with inoperable CTEPH may improve their clinical status, hemodynamics, and anti-inflammatory status.
- 20 February 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (1) , 53-61
Efficacy of intermittent inhaled iloprost in inoperable chronic thromboembolic pulmonary hypertension
PH (pulmonary hypertension) targeted therapy may play an essential role in chronic thromboembolic pulmonary hypertension (CTEPH) patients considered inoperable. Given the limited number of PH-targeted drugs approved for CTEPH, reliable long-term data are necessary on the effects of PH-targeted drugs in patients with inoperable CTEPH. We aimed to evaluate the efficacy and safety of intermittent inhaled iloprost in inoperable CTEPH. Methods. The open randomized controlled trial included 22 inoperable CTEPH patients (aged (Me (25%; 75%)) 48,3 (38,4; 59,5) years; 63.6% females; 9.1% with WHO functional class (FC) IV, 72.7% with WHO-FC III, 18.2% with WHO-FC II; 6-minute walking test (6-MWT) distance of 348 (145; 443) m; mean pulmonary artery pressure (mPAP) of 41.8 (29.3; 52.8) mmHg; tricuspid annular plane systolic excursion (TAPSE) of 16.3 (14.5; 18.2) mm; plasma NT-proBNP of 853.8 (562.2; 1124.2) pg/mL). The patients were enrolled 3 – 6 months after acute pulmonary embolism and were randomized 1:1 to receive either standard therapy with vitamin K antagonists and, if indicated, oxygen and diuretics or inhaled iloprost 5.0 µg / inhalation 4 times a day for 2 weeks every 3 months for 2 years in addition to the standard of care. Efficacy endpoints included changes from baseline in 6-MWT, WHO-FC, echo-parameters, inflammatory markers, time to clinical worsening, and all-cause mortality. Results. At baseline (prior to therapy), there were no significant differences between iloprost and control groups. Levels of C-reactive protein and the interleukin (IL)-1b, IL-6, IL-8, γ-IF, and TNF-α cytokines were increased. At month 24, a mean 6-MWT distance increased by 215 m (p < 0.001) in the patients receiving inhaled iloprost and by 137 m in the control patients (p < 0.01). The control-adjusted difference was +78 m (p = 0.03). WHO-FC improved by two classes in 63.6% in iloprost group vs 0% in the control group (p = 0.028), by one class in 36.4% vs 30% (p = 0.091), and remained the same in 0% vs 70 % (p = 0.018), respectively. Inhaled iloprost delayed the time to clinical worsening (p = 0.0064). Improvements were noted in control-adjusted changes in ePASP (–18.6 mmHg; p = 0.0065), TAPSE (+2.4 mm; p = 0.028), and plasma NT-proBNP (–256.9 pg/mL; p < 0.01). The levels of inflammation decreased significantly in the iloprost group, while remained unchanged in the control group. Combination therapy with inhaled iloprost was tolerated well. One patient died in the control group (p = 0.093). Conclusion. Long-term intermittent inhaled iloprost for patients with inoperable CTEPH may improve their clinical status, hemodynamics, and anti-inflammatory status.
- Open Access
- 11 December 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (4S) , 4791
Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts
At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.
- 11 December 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (4S) , 4791
Open AccessApproaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts
At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.
- Open Access
- 29 June 2021
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 27 (2) , 146-169
Diagnosis and treatment of hypertensive disorders of pregnancy: a narrative review
The paper overviews classification, diagnosis and treatment of hypertensive disorders of pregnancy and early postpartum period (chronic hypertension (HTN), gestational HTN, pre-eclampsia) provided by different societies of cardiology and obstetrics and gynecology. The definition of pre-eclampsia offered by the International Society for the Study of Hypertension in Pregnancy (ISSHP) in 2018 and supported by the International Federation of Gynecology and Obstetrics (FIGO) in 2019, its screening and prevention are considered. All treatment options of moderate and severe HTN in pregnancy are reviewed. A new US Food and Drug Administration (FDA) classification system of drug therapy for pregnancy and lactation Pregnancy and Lactation Labelling Rule (PLLR, 2015) is presented. Treatment goals of HTN and blood pressure (BP) thresholds in pregnancy as well as risk factors, causes, clinical presentation, diagnostic workup and management of hypertensive emergencies in pregnancy are provided. We discuss the evidence of BP ≥ 130/80 mmHg as a factor of high maternal and neonatal risks proposed by the American College of Cardiology/American Heart Association (2017) as the HTN criteria in pregnancy.
- 29 June 2021
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 27 (2) , 146-169
Open AccessDiagnosis and treatment of hypertensive disorders of pregnancy: a narrative review
The paper overviews classification, diagnosis and treatment of hypertensive disorders of pregnancy and early postpartum period (chronic hypertension (HTN), gestational HTN, pre-eclampsia) provided by different societies of cardiology and obstetrics and gynecology. The definition of pre-eclampsia offered by the International Society for the Study of Hypertension in Pregnancy (ISSHP) in 2018 and supported by the International Federation of Gynecology and Obstetrics (FIGO) in 2019, its screening and prevention are considered. All treatment options of moderate and severe HTN in pregnancy are reviewed. A new US Food and Drug Administration (FDA) classification system of drug therapy for pregnancy and lactation Pregnancy and Lactation Labelling Rule (PLLR, 2015) is presented. Treatment goals of HTN and blood pressure (BP) thresholds in pregnancy as well as risk factors, causes, clinical presentation, diagnostic workup and management of hypertensive emergencies in pregnancy are provided. We discuss the evidence of BP ≥ 130/80 mmHg as a factor of high maternal and neonatal risks proposed by the American College of Cardiology/American Heart Association (2017) as the HTN criteria in pregnancy.